Understanding LGALS16: A Potential Drug Target and Biomarker (G148003)

Target Name: LGALS16

NCBI ID: G148003

LGALS16

Understanding LGALS16: A Potential Drug Target and Biomarker

LGALS16 (LEG16_HUMAN) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 16 and is responsible for the production of a protein known as LGALS16.

LGALS16 is a protein that is expressed in many different tissues and cells in the body. It is involved in a variety of cellular processes, including cell adhesion, migration, and the regulation of cell growth. The protein has also been shown to play a role in the development and progression of various diseases, including cancer.

One of the key reasons why LGALS16 is considered a potential drug target is its involvement in the regulation of cell growth and the development of cancer. Many studies have shown that the levels of LGALS16 are elevated in various types of cancer, and that the levels of the protein have been associated with the severity of these diseases. Additionally, research has also shown that LGALS16 is involved in the development of various types of cancer, including breast, ovarian, and prostate cancer.

Another potential drug target for LGALS16 is its role in cell adhesion and migration. Many studies have shown that LGALS16 is involved in the regulation of cell adhesion and that it plays a role in the movement of cells through the body. This is important because the ability of cells to move and adhere to other cells is a key factor in the development and progression of many diseases, including cancer.

In addition to its potential as a drug target, LGALS16 is also considered a biomarker for the diagnosis and treatment of various diseases. Many studies have shown that the levels of LGALS16 are elevated in a variety of diseases, including cancer, and that the levels of the protein have been used as a diagnostic marker for these diseases. Additionally, research has also shown that LGALS16 is involved in the regulation of cellular processes that are important in the development and progression of many diseases, including cancer.

Overall, LGALS16 is a protein that has been identified as a potential drug target and biomarker for the treatment of various diseases. Further research is needed to fully understand the role of LGALS16 in these processes and to develop effective treatments for the treatment of these diseases.

Protein Name: Galectin 16

Functions: Binds lactose with high affinity. Strong inducer of T-cell apoptosis

The "LGALS16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGALS16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets